Thyroid Eye Disease: Multidisciplinary Management of Treatment-Associated Hearing Loss (Online CME Monograph)
This educational activity is intended to help clinicians evaluate real-world data pertaining to hearing dysfunction associated with thyroid eye disease treatment with the insulin-like growth factor 1 receptor antagonist teprotumumab.
Category
- Ophthalmology
- Ophthalmology/Neuro-Ophthalmic
Format
- Monograph
Credits
- 1.50 AMA PRA Category 1 Credit™
- 1.50 Participation